|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,880,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
47,000 |
47,000 |
Total Buy Value |
$0 |
$0 |
$38,445 |
$38,445 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
7 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gilead Sciences Inc |
10% Owner |
|
2023-12-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
18,759,465 |
|
- |
|
Kandera Reinhard |
Chief Financial Officer |
|
2023-08-21 |
4 |
B |
$0.73 |
$5,075 |
D/D |
7,000 |
43,092 |
2.81 |
- |
|
Kandera Reinhard |
Chief Financial Officer |
|
2023-08-16 |
4 |
B |
$0.71 |
$5,712 |
D/D |
8,000 |
36,092 |
2.81 |
- |
|
Aldag Jorn |
Chief Executive Officer |
|
2023-07-11 |
4 |
B |
$0.83 |
$4,142 |
D/D |
5,000 |
71,952 |
2.73 |
- |
|
Aldag Jorn |
Chief Executive Officer |
|
2023-07-07 |
4 |
B |
$0.81 |
$4,050 |
D/D |
5,000 |
66,952 |
2.73 |
- |
|
Aldag Jorn |
Chief Executive Officer |
|
2023-07-05 |
4 |
B |
$0.89 |
$4,450 |
D/D |
5,000 |
61,952 |
2.73 |
- |
|
Aldag Jorn |
Chief Executive Officer |
|
2023-07-03 |
4 |
B |
$0.89 |
$4,456 |
D/D |
5,000 |
56,952 |
2.73 |
- |
|
Kandera Reinhard |
Chief Financial Officer |
|
2023-06-30 |
4 |
B |
$0.88 |
$10,560 |
D/D |
12,000 |
28,092 |
2.81 |
- |
|
Schlienger Katia |
Chief Medical OfficerOfficer |
|
2023-03-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,300 |
|
- |
|
Baker Christine D. |
Chief Business Officer |
|
2022-02-01 |
4 |
A |
$3.00 |
$40,974 |
D/D |
13,658 |
16,158 |
|
- |
|
Orlinger Klaus |
Executive VP, Research |
|
2022-02-01 |
4 |
A |
$3.00 |
$27,564 |
D/D |
9,188 |
10,404 |
|
- |
|
Kandera Reinhard |
Chief Financial Officer |
|
2022-02-01 |
4 |
A |
$3.00 |
$42,168 |
D/D |
14,056 |
16,092 |
|
- |
|
Necina Roman |
Chief Technology Officer |
|
2022-02-01 |
4 |
A |
$3.00 |
$38,676 |
D/D |
12,892 |
14,876 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2022-02-01 |
4 |
A |
$3.00 |
$44,799 |
D/D |
14,933 |
100,240 |
|
- |
|
Aldag Jorn |
Chief Executive Officer |
|
2022-02-01 |
4 |
A |
$3.00 |
$143,472 |
D/D |
47,824 |
51,952 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2021-12-21 |
4 |
S |
$2.49 |
$37,223 |
D/D |
(14,949) |
85,307 |
|
- |
|
Matushansky Igor |
Chief Medical Officer |
|
2021-12-21 |
4 |
OE |
$0.10 |
$2,285 |
D/D |
22,853 |
87,512 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-04-21 |
4 |
S |
$11.60 |
$3,812,386 |
D/D |
(328,620) |
3,177,574 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-29 |
4 |
AS |
$13.67 |
$503,570 |
D/D |
(36,829) |
3,506,194 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-26 |
4 |
AS |
$13.69 |
$481,642 |
D/D |
(35,171) |
3,543,023 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-25 |
4 |
AS |
$13.12 |
$374,569 |
D/D |
(28,546) |
3,578,194 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-24 |
4 |
AS |
$13.70 |
$721,616 |
D/D |
(52,690) |
3,606,740 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-23 |
4 |
AS |
$13.91 |
$556,476 |
D/D |
(40,000) |
3,659,430 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-22 |
4 |
AS |
$14.54 |
$589,263 |
D/D |
(40,534) |
3,699,430 |
|
- |
|
Sofinnova Partners Sas |
10% Owner |
|
2021-03-19 |
4 |
AS |
$14.60 |
$2,427,739 |
D/D |
(166,230) |
3,739,964 |
|
- |
|
59 Records found
|
|
Page 1 of 3 |
|
|